Claritas Pharmaceuticals, Inc. Stock

CLAZF

CA1806342061

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 04:16:04 28/02/26 am AEDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

Valuation: Claritas Pharmaceuticals, Inc.

Market Cap	5.37M 3.83M 3.32M 3.09M 2.84M 364M 5.43M 36.33M 14.26M 182M 14.38M 14.07M 603M	P/E 2019	-0.74x	P/E 2020	0.13x
Enterprise Value	6.29M 4.49M 3.89M 3.62M 3.33M 427M 6.36M 42.56M 16.7M 213M 16.85M 16.48M 707M	EV / Sales 2019	-	EV / Sales 2020	-
Free-Float	99.74%	Yield 2019 *	-	Yield 2020	-

* Estimated data More valuation ratios

Chart: Claritas Pharmaceuticals, Inc.

Dynamic Chart

Managers and Directors: Claritas Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Farrell CEO	Chief Executive Officer	76	21/06/2017
Victoria Rudman DFI	Director of Finance/CFO	58	29/06/2018

Director	Title	Age	Since
Robert Farrell CHM	Chairman	76	18/03/2021

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CLARITAS PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	37
LONZA GROUP AG	+0.75%	-0.91%	+3.59%	+15.26%	48.57B
REVOLUTION MEDICINES, INC.	+1.98%	+9.05%	+413.94%	+532.17%	41.95B
IQVIA HOLDINGS INC.	+3.44%	-4.65%	+28.34%	+8.81%	38.85B
BEONE MEDICINES AG	+1.40%	+0.10%	+6.61%	+61.93%	37.24B
CELLTRION, INC.	+2.42%	+5.72%	+12.38%	+44.79%	30.67B
ASCENDIS PHARMA A/S	-0.16%	-3.11%	-	-	16.1B
MEDPACE HOLDINGS, INC.	+2.20%	+0.48%	+34.71%	+127.15%	16.41B
EUROFINS SCIENTIFIC SE	+0.34%	+1.92%	+8.24%	+19.07%	13.97B
ICON PUBLIC LIMITED COMPANY	+4.25%	-8.23%	-1.49%	-35.46%	12.62B
Average	+1.66%	-0.70%	+63.29%	+96.72%	25.64B
Weighted average by Cap.	+1.83%	-0.12%	+82.95%	+120.66%

See all sector performances

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâ€™s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
CLAZF Stock

As early as today, start finding the best investment opportunities!

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.4
10 years	0		15.31

Date	Insider	Type	Quantity	% Market Cap.
11/10/21	Andrew Salzman	Buy	118,000	0.3332%
11/10/21	Andrew Salzman	Buy	152,500	0.4307%
11/10/21	Andrew Salzman	Buy	24,500	0.0692%

	2019	2020
Net sales	-	-
Net income	-21.21M -15.13M -13.11M -12.22M -11.24M -1.44B -21.45M -144M -56.35M -720M -56.83M -55.58M -2.38B	4.21M 3M 2.6M 2.42M 2.23M 286M 4.26M 28.49M 11.18M 143M 11.28M 11.03M 473M
Net Debt	704K 502K 435K 405K 373K 47.75M 712K 4.76M 1.87M 23.89M 1.89M 1.84M 79.13M	920K 656K 568K 530K 487K 62.4M 930K 6.23M 2.44M 31.22M 2.46M 2.41M 103M

Claritas Pharmaceuticals, Inc. Stock

Stocks

CLAZF

CA1806342061

Biotechnology & Medical Research

Valuation: Claritas Pharmaceuticals, Inc.

Chart: Claritas Pharmaceuticals, Inc.

Course Extremes

Managers and Directors: Claritas Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile